Modified weekly @entity900 -based chemotherapy is acceptable in postoperative concurrent chemoradiotherapy for locally advanced XXXX .

@entity1 @entity135 @entity137 @entity5 @entity900 @entity33
Background. Triweekly @entity900 -based postoperative concurrent chemoradiotherapy (CCRT) has high intolerance and @entity137 in locally advanced @entity135 (LAHNC). We evaluated the effect of a modified weekly @entity900 -based chemotherapy in postoperative CCRT. Methods. A total of 117 @entity1 with LAHNC were enrolled between December 2007 and December 2012. Survival, compliance/adverse events, and independent prognostic factors were analyzed. Results. Median follow-up time was 30.0 (3.1-73.0) months. Most @entity1 completed the entire course of postoperative CCRT (radiotherapy >=  60   Gy, 94.9%; >= 6 times weekly chemotherapy, 75.2%). Only 17.1% @entity1 required hospital admission. The most common adverse effect was grade 3/4 @entity33 (28.2%). No @entity1 died due to protocol-related adverse effects. Multivariate analysis revealed the following independent prognostic factors: @entity5 , extracapsular spread, and total radiation dose. Two-year progression-free survival and overall survival rates were 70.9% and 79.5%, respectively. Conclusion. Modified weekly @entity900 -based chemotherapy is an acceptable regimen in postoperative CCRT for LAHNC.
